MLMargaret C. Lunn-Halbert

Margaret C. Lunn-Halbert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Margaret C. Lunn-Halbert has a total of 159 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Biomolecular design through latent reasoning with RFD4-Proteina

    by Nathaniel Corley, Kieran Didi, Maxwell W. Kazman, Rafael I. Brent, Magnus S. Bauer, Riti Biswas, Julia E. Bonzanini, Adam M. Chazin-Gray, Jie Chen, Andrew Favor, et al.

    Biomolecular design requires finding chemically and geometrically compatible arrangements of interacting atoms and molecules. The complexity of problems which can be tackled by deep learning design models is limited by both the molecular landscape they encompass and their ability to explore that landscape effectively. Here we introduce RFD4-Proteina, which addresses these limitations through intrinsic and extrinsic reasoning within a shared chemical and conformational latent space. The latent space encompasses standard and modified amino acids, sugars, DNA, and RNA, with force-field supervision favoring physically plausible atomic reconstructions. Within this space, intrinsic reasoning uses recurrent refinement to adaptively allocate computation, while extrinsic reasoning guides search with arbitrary constraints such as energetic or geometric criteria. Across in silico protein design benchmarks, RFD4-Proteina achieves higher design success rates at greater generation throughput than all previous methods evaluated, with further gains from conformational flexibility, recurrent refinement, and search. The same model performs equivalently to or better than state-of-the-art specialist methods for side-chain packing, sequence design, conformational sampling, and design refinement. We demonstrate the power and versatility of RFD4-Proteina experimentally by designing specific and cross-reactive binders to therapeutically relevant targets, recognizing phosphorylations, controlling glycosylation, and creating enzymes that catalyze both bond-breaking and bond-forming reactions, including a first proof-of-concept demonstration of a de novo designed enzyme for active pharmaceutical ingredient synthesis. By unifying diverse chemistry, conformational flexibility, and scalable reasoning in a single physically grounded latent space, RFD4-Proteina expands the frontier of biomolecular design.

  • Open Access

    Programming N-linked glycan composition through de novo protein design

    by Margaret C Lunn-Halbert, Joel D Allen, Rohith Krishna, Anna Manchenko, Xinting Li, Edward D Lopatto, Jerome Pinkner, Carolina Moller, Woody Ahern, Johnny Mendoza, et al.

    N-linked glycans are ubiquitous post-translational modifications that mediate diverse biological processes, including cell signaling and adhesion, molecular recognition, and host-pathogen interactions. Despite their importance, N-linked glycans have largely remained beyond the reach of biomolecular design due to a lack of methods capable of jointly modeling glycans and protein structure. Here, we develop a general all-atom computational pipeline for creating de novo glycoproteins in which the amino acid sequence encodes both the location and composition of N-linked glycans. The method uses three-dimensional protein structure to tune glycan accessibility to processing enzymes in the eukaryotic secretory pathway. Systematic increases in steric restriction progressively reduced processing, shifting glycans from heterogeneous complex-type structures toward increasingly underprocessed oligomannose-type species resembling those found on many viral glycoproteins. Despite this programmed restriction, the resulting oligomannose glycans remained accessible for biological recognition, inhibiting uropathogenic Escherichia coli adhesion to human bladder cells and binding mannose-binding lectin. These results establish steric control of N-glycan processing as a genetically encodable design principle and extend computational protein design to functional glycoproteins with programmed composition.


  • Open Access

    [211At]Astatine-Based Conditioning with a Humanized CD45 Antibody for Autologous Hematopoietic Stem Cell Gene Therapy

    by Stefan Radtke, George S. Laszlo, Kyle Swing, Andrea Repele, Jacob W Barton, David J King, Dnyanada Pande, Mark R Enstrom, Junyang Li, Carl B Wolf, et al.

    Successful transplantation of autologous gene-modified hematopoietic stem/progenitor cells (HSPCs) requires efficient ablation of resident hematopoietic stem cells. Since conventional myeloablative conditioning regimens are associated with non-hematologic toxicities, we evaluated CD45-directed radioimmunotherapy (RIT) using the a-emitter astatine-211 (211At) before transplantation of ex vivo gene-edited autologous HSPCs as an alternative in nonhuman primates. We humanized the CD45 antibody, BC8 (HuBC8), and labeled it with 211At. As a model, mobilized CD34+ HSPCs were multiplex gene-edited using an adenine base editor, modifying the HBG promoter to reactivate fetal hemoglobin (HbF) and deleting CD33. Two animals each received 300 or 400 µCi/kg of 211At. In contrast to historic controls conditioned with total body irradiation, CD45-RIT animals did not show any noticeable non-hematopoietic toxicities and were almost entirely transfusion independent with rapid recovery of neutrophils and platelets. 211At enabled dose-dependent engraftment of gene-edited cells. A new single cell sequencing assay revealed up to 70% combined mono- and bi-allelic gene-editing efficiency in the blood, consistent with complete replacement of the bone marrow stem cell compartment. Assessment by bulk analysis underestimated the frequency of gene-edited cells, highlighting the importance of a single cell readout. Single cell sequencing further confirmed stable and unbiased contribution of multiplex-edited HSPCs to all mature lineages in the blood, providing high-resolution data assuring successful replacement upon autologous HSPC gene therapy. Levels of edited cells remained stable for the entire follow-up of >18 months. Together, these studies identify 211At-CD45 RIT as a targeted alternative for myeloablative conditioning for autologous gene therapy.


  • Open Access

    High-Throughput De Novo Protein Design Yields Novel Immunomodulatory Agonists

    by Mohamad Abedi, Marc Expòsit, Brian Coventry, Divij Mathew, Shruti Jain, Aditya Krishnakumar, Inna Goreshnik, Sophie L. Gray-Gaillard, Margaret Lunn-Halbert, Ta-Yi Yu, et al.

    Cytokines regulate cell behavior by bringing together specific receptor subunits to trigger downstream signaling. Designed molecules that bring together non-natural receptor pairs could have novel signaling responses and cell specificities. We present a high-throughput de-novo design approach to create novel cytokines by generating and fusing pairs of computationally designed binders. By combining 33 designed receptor-binding domains, we generated over a thousand potential de novo designed “Novokines”, of which 75 activated pSTAT signaling in peripheral blood mononuclear cells. We characterized 18 of these, including new pairings of established common receptors, cross-family pairings such as TrkA-γcommon, and a series of pairings with interferon receptor-1 (IFNAR1), revealing that IFNAR1 can function as a versatile common receptor similar to γcommon or βcommon. We identify novokines that drive monocyte proliferation, T cell survival and CD4 + T cell-specific proliferation. Our framework provides a blueprint for expanding the understanding of cytokine signaling and generating novel therapeutic proteins.


  • Preclinical characterization of the anti-leukemia activity of the CD123 antibody-drug conjugate, pivekimab sunirine (IMGN632)

    by Frances M. Cole, George S. Laszlo, Margaret C. Lunn-Halbert, Allie R. Kehret, Patrick A. Zweidler-McKay, Eduardo Rodríguez-Arbolí, David Wu, Kyle Nyberg, Junyang Li, Sheryl Y. T. Lim, et al.


  • Open Access

    Optimizing Siglec-8-Directed Immunotherapy for Eosinophilic and Mast Cell Disorders

    by Sheryl Y. T. Lim, Jenny Huo, George S. Laszlo, Frances M. Cole, Allie R. Kehret, Junyang Li, Margaret C. Lunn-Halbert, Jasmyn L. Persicke, Peter B. Rupert, Roland K. Strong, et al.

    Background/Objective: Current treatments for eosinophilic and mast cell disorders are often ineffective. One promising target to improve outcomes is sialic acid-binding immunoglobulin-like lectin-8 (Siglec-8). As limitations, there are few Siglec-8 monoclonal antibodies (mAbs) available to date, and Siglec-8-directed treatments have so far primarily focused on unconjugated mAbs, which may be inadequate, especially against mast cells. Methods: Here, we used transgenic mice to raise a diverse panel of fully human mAbs that either recognize the V-set domain, membrane-distal C2-set domain, or membrane-proximal C2-set domain of full-length Siglec-8 as a basis for novel therapeutics. Results: All mAbs were efficiently internalized into Siglec-8-expressing cells, suggesting their potential to deliver cytotoxic payloads. Tool T cell-engaging bispecific antibodies (BiAbs) and chimeric antigen receptor (CAR)-modified natural killer (NK) cells using single-chain variable fragments from Siglec-8 mAbs showed highly potent cytolytic activity against Siglec-8-positive cells even in cases of very low target antigen abundance, whereas they elicited no cytolytic activity against Siglec-8-negative target cells. Siglec-8V-set-directed T cell-engaging BiAbs and Siglec-8V-set-directed CAR-modified NK cells induced substantially greater cytotoxicity against cells expressing an artificial smaller Siglec-8 variant containing only the V-set domain than cells expressing full-length Siglec-8, consistent with the notion that targeting membrane-proximal epitopes enhances effector functions of Siglec-8 antibody-based therapeutics. Indeed, unconjugated Siglec-8C2-set mAbs, Siglec-8C2-set-directed T cell-engaging BiAbs, and Siglec-8C2-set-directed CAR-modified NK cells showed high antigen-specific cytolytic activity against Siglec-8-positive human cell lines and primary patient eosinophils. Conclusions: Together, these data demonstrate Siglec-8-directed immunotherapies can be highly potent, supporting their further development for eosinophilic and mast cell disorders.


  • Open Access

    Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET® CC-96191

    by Margaret C. Lunn-Halbert, George S. Laszlo, Sarah Erraiss, Mark T. Orr, Heidi K. Jessup, Heather J. Thomas, Henry Chan, Mahan A. Jahromi, Jonathan Lloyd, Ann F. Cheung, et al.

    Increasing efforts are focusing on natural killer (NK) cell immunotherapies for AML. Here, we characterized CC-96191, a novel CD33/CD16a/NKG2D immune-modulating TriNKET®. CC-96191 simultaneously binds CD33, NKG2D, and CD16a, with NKG2D and CD16a co-engagement increasing the avidity for, and activation of, NK cells. CC-96191 was broadly active against human leukemia cells in a strictly CD33-dependent manner, with maximal efficacy requiring the co-engagement of CD16a and NKG2D. A frequent CD33 single nucleotide polymorphism, R69G, reduced CC-96191 potency but not maximal activity, likely because of reduced CD33 binding. Similarly, the potency, but not the maximal activity, of CC-96191 was reduced by high concentrations of soluble CD33; in contrast, the soluble form of the NKG2D ligand MICA did not impact activity. In the presence of CD33+ AML cells, CC-96191 activated NK cells but not T cells; while maximum anti-AML efficacy was similar, soluble cytokine levels were 10- to >100-fold lower than with a CD33/CD3 bispecific antibody. While CC-96191-mediated cytolysis was not affected by ABC transporter proteins, it was reduced by anti-apoptotic BCL-2 family proteins. Finally, in patient marrow specimens, CC-96191 eliminated AML cells but not normal monocytes, suggesting selectivity of TriNKET-induced cytotoxicity toward neoplastic cells. Together, these findings support the clinical exploration of CC-96191 as in NCT04789655.


  • Development of [211At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignancies

    by George S. Laszlo, Johnnie J. Orozco, Allie R. Kehret, Margaret C. Lunn, Jenny Huo, Donald K. Hamlin, D. Scott Wilbur, Shannon L. Dexter, Melissa L. Comstock, Shyril O’sTeen, et al.

    Radioimmunotherapy (RIT) has long been pursued to improve outcomes in acute leukemia and higher-risk myelodysplastic syndrome (MDS). Of increasing interest are alpha-particle-emitting radionuclides such as astatine-211 (211At) as they deliver large amounts of radiation over just a few cell diameters, enabling efficient and selective target cell kill. Here, we developed 211At-based RIT targeting CD123, an antigen widely displayed on acute leukemia and MDS cells including underlying neoplastic stem cells. We generated and characterized new murine monoclonal antibodies (mAbs) specific for human CD123 and selected four, all of which were internalized by CD123+ target cells, for further characterization. All mAbs could be conjugated to a boron cage, isothiocyanatophenethyl-ureido-closo-decaborate(2-) (B10), and labeled with 211At. CD123+ cell targeting studies in immunodeficient mice demonstrated specific uptake of 211At-labeled anti-CD123 mAbs in human CD123+ MOLM-13 cell tumors in the flank. In mice injected intravenously with MOLM-13 cells or a CD123NULL MOLM-13 subline, a single dose of up to 40 µCi of 211At delivered via anti-CD123 mAb decreased tumor burdens and substantially prolonged survival dose dependently in mice bearing CD123+ but not CD123– leukemia xenografts, demonstrating potent and target-specific in vivo anti-leukemia efficacy. These data support the further development of 211At-CD123 RIT toward clinical application.


  • Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy

    by Colin D. Godwin, George S. Laszlo, Salvatore Fiorenza, Eliotte E. Garling, Tinh-Doan Phi, Olivia M. Bates, Colin E. Correnti, Benjamin G. Hoffstrom, Margaret C. Lunn, Olivier Humbert, et al.

    There is increasing interest in targeting CD33 in malignant and non-malignant disorders. In acute myeloid leukemia, longer survival with the CD33 antibody-drug conjugate gemtuzumab ozogamicin (GO) validates this strategy. Still, GO benefits only some patients, prompting efforts to develop more potent CD33-directed therapeutics. As one limitation, CD33 antibodies typically recognize the membrane-distal V-set domain. Using various artificial CD33 proteins, in which this domain was differentially positioned within the extracellular portion of the molecule, we tested whether targeting membrane-proximal epitopes enhances the effector functions of CD33 antibody-based therapeutics. Consistent with this idea, a CD33V-set/CD3 bispecific antibody (BsAb) and CD33V-set-directed chimeric antigen receptor (CAR)-modified T cells elicited substantially greater cytotoxicity against cells expressing a CD33 variant lacking the entire C2-set domain than cells expressing full-length CD33, whereas cytotoxic effects induced by GO were independent of the position of the V-set domain. We therefore raised murine and human antibodies against the C2-set domain of human CD33 and identified antibodies that bound CD33 regardless of the presence/absence of the V-set domain (“CD33PAN antibodies”). These antibodies internalized when bound to CD33 and, as CD33PAN/CD3 BsAb, had potent cytolytic effects against CD33+ cells. Together, our data provide the rationale for further development of CD33PAN antibody-based therapeutics.


  • The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia

    by Colin D. Godwin, George S. Laszlo, Brent L. Wood, Colin E. Correnti, Olivia M. Bates, Eliotte E. Garling, Zhengwei J. Mao, Mary E. Beddoe, Margaret C. Lunn, Olivier Humbert, et al.